For the first quarter of the fiscal year ending March 2027, consolidated net sales were 36,590 million yen, up 14.4% YoY; operating profit was 163.5 million yen; ordinary income was 156.383 million yen; net income attributable to owners of the parent was 1,360.32 thousand yen, with a substantial increase. By segment, Discoveries\/Drug Discovery Support posted a sales decline but narrowed losses, while Investment & Consulting showed a substantial increase in both sales and profit. For full-year guidance, the previous forecast is kept unchanged.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2342","jir_company_name":"Transgenic Group Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-12","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/2342-20260812-01.pdf","jir_short_summary":"For the first quarter of the fiscal year ending March 2027, consolidated net sales were 36,590 million yen, up 14.4% YoY; operating profit was 163.5 million yen; ordinary income was 156.383 million yen; net income attributable to owners of the parent was 1,360.32 thousand yen, with a substantial increase. By segment, Discoveries\/Drug Discovery Support posted a sales decline but narrowed losses, while Investment & Consulting showed a substantial increase in both sales and profit. For full-year guidance, the previous forecast is kept unchanged.","jir_summary":"### Overview of Results\nFor the quarterly cumulative consolidated period, net sales were 3,659,068 thousand yen, up 14.4% YoY, and operating profit rose substantially to 163,500 thousand yen. Ordinary income was 156,383 thousand yen, and net income attributable to owners of the parent rose to 136,032 thousand yen, with significant improvements. Although the Discoveries\/Drug Discovery Support segment remained in the red, the loss narrowed. The Investment & Consulting business saw a substantial increase in both sales and profit due to a recovery in e-commerce and large orders. The company will pursue profitability improvements through thorough cost management across the group.\n\n### Outlook and Asset Position\nFull-year earnings forecast is unchanged from the May 2026 forecast. The financial condition remains at appropriate levels for current assets and liabilities, with an equity ratio of 50.1% maintaining financial health. No new investment plans have been disclosed, but policies continue toward streamlining operations and reducing costs. An earnings briefing is scheduled, and supplementary materials will be provided; attention will be on future order momentum and progress in non-clinical trials.","jir_financial_highlights":"Net Sales: 3,659,068\u5343\u5186 (YoY +14.4%)\nOperating Profit: 163,500\u5343\u5186 (YoY +261.2%)\nOrdinary Income: 156,383\u5343\u5186 (YoY +154.3%)\nNet Income Attributable to Owners of Parent: 136,032\u5343\u5186 (YoY +404.6%)\nTotal Assets: 9,728,846\u5343\u5186 (vs end of previous period: unchanged\/slightly up)\nEquity Ratio: 50.1% (YoY up)","jir_category":"","jir_hashtags":"#TransgenicGroup, #FinancialSummary, #BusinessTrends","jir_key_figures":"Net Sales: 3,659,068\u5343\u5186\nOperating Profit: 163,500\u5343\u5186\nNet Income Attributable to Owners of Parent: 136,032\u5343\u5186","jir_meta_title":"Transgenic Group Q1 FY2027 Financial Results | Net Sales 3,659 million yen, Operating Profit 16.5 million yen","jir_meta_description":"Summary of Transgenic Group's Q1 FY2027 financial results. Net sales increased 14.4% YoY, operating income and net income rose significantly. Drug discovery support saw a decline, but losses narrowed. Full-year guidance unchanged. Earnings briefing information available.","jir_og_title":"Transgenic Group Q1 FY2027 Summary of Results","jir_og_description":"Transgenic Group's Q1 results show revenue and profit growth. Explanations by segment and future outlook. Earnings briefing scheduled.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60051,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-102967","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n